MA38147B1 - Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique - Google Patents

Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique

Info

Publication number
MA38147B1
MA38147B1 MA38147A MA38147A MA38147B1 MA 38147 B1 MA38147 B1 MA 38147B1 MA 38147 A MA38147 A MA 38147A MA 38147 A MA38147 A MA 38147A MA 38147 B1 MA38147 B1 MA 38147B1
Authority
MA
Morocco
Prior art keywords
compounds
antagonist activity
beta2 adrenergic
adrenergic receptor
receptor antagonist
Prior art date
Application number
MA38147A
Other languages
English (en)
Other versions
MA38147A1 (fr
Inventor
Fabio Rancati
Ian Linney
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MA38147A1 publication Critical patent/MA38147A1/fr
Publication of MA38147B1 publication Critical patent/MA38147B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
    • A61M16/10—Preparation of respiratory gases or vapours
    • A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention concerne des composés agissant à la fois en tant qu'antagonistes du récepteur muscarinique et agonistes du récepteur bêta2 adrénergique, des procédés pour leur préparation, des compositions les comprenant, des utilisations thérapeutiques et des combinaisons avec d'autres principes pharmaceutiquement actifs.
MA38147A 2012-12-06 2013-12-05 Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique MA38147B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12195891 2012-12-06
PCT/EP2013/075661 WO2014086924A1 (fr) 2012-12-06 2013-12-05 Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique

Publications (2)

Publication Number Publication Date
MA38147A1 MA38147A1 (fr) 2018-03-30
MA38147B1 true MA38147B1 (fr) 2018-09-28

Family

ID=47323975

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38147A MA38147B1 (fr) 2012-12-06 2013-12-05 Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique

Country Status (37)

Country Link
US (2) US8987299B2 (fr)
EP (2) EP3345904B1 (fr)
JP (1) JP6421989B2 (fr)
KR (2) KR102240459B1 (fr)
CN (1) CN104822678B (fr)
AR (1) AR093825A1 (fr)
AU (1) AU2013354043C1 (fr)
BR (1) BR112015012730B1 (fr)
CA (1) CA2893626C (fr)
CL (1) CL2015001483A1 (fr)
CO (1) CO7400870A2 (fr)
CY (2) CY1120159T1 (fr)
DK (2) DK2928889T3 (fr)
EA (1) EA030552B1 (fr)
ES (2) ES2670686T3 (fr)
GE (1) GEP20186839B (fr)
HR (2) HRP20180915T1 (fr)
HU (2) HUE051394T2 (fr)
IL (1) IL239182B (fr)
LT (2) LT2928889T (fr)
MA (1) MA38147B1 (fr)
MX (1) MX369311B (fr)
NZ (1) NZ708738A (fr)
PE (1) PE20151216A1 (fr)
PH (1) PH12015501247B1 (fr)
PL (2) PL2928889T3 (fr)
PT (2) PT3345904T (fr)
RS (2) RS60864B1 (fr)
SA (1) SA515360514B1 (fr)
SG (2) SG10201704032RA (fr)
SI (2) SI2928889T1 (fr)
TN (1) TN2015000244A1 (fr)
TR (1) TR201808698T4 (fr)
TW (1) TWI637954B (fr)
UA (1) UA118181C2 (fr)
WO (1) WO2014086924A1 (fr)
ZA (1) ZA201503965B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITRM20110083U1 (it) 2010-05-13 2011-11-14 De La Cruz Jose Antonio Freire Piastra per la costruzione di carrelli per aeroplani
EP2386555A1 (fr) 2010-05-13 2011-11-16 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agoniste bêta 2 adrénergique et antagoniste muscarinique m3
EP2592078A1 (fr) 2011-11-11 2013-05-15 Almirall, S.A. Nouveaux dérivés de cyclohéxylamine dotés d'activités agonistes bêta 2 adrénergique et antagoniste muscarinique M3
SG10201704032RA (en) * 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物
ES2750523T3 (es) 2012-12-18 2020-03-26 Almirall Sa Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
TWI643853B (zh) 2013-02-27 2018-12-11 阿爾米雷爾有限公司 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類
TWI641373B (zh) 2013-07-25 2018-11-21 阿爾米雷爾有限公司 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物
TWI703138B (zh) 2015-02-12 2020-09-01 義大利商吉斯藥品公司 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物
AR104828A1 (es) 2015-06-01 2017-08-16 Chiesi Farm Spa COMPUESTOS CON ACTIVIDAD ANTAGONISTA DE LOS RECEPTORES MUSCARÍNICOS Y ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO
HUE056260T2 (hu) * 2015-11-16 2022-02-28 Chiesi Farm Spa Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
WO2017093208A1 (fr) 2015-12-03 2017-06-08 Chiesi Farmaceutici S.P.A. Composés ayant une activité d'antagoniste des récepteurs muscariniques et d'agoniste des récepteurs adrénergiques bêta2
WO2018011090A1 (fr) 2016-07-13 2018-01-18 Chiesi Farmaceutici S.P.A. Composés d'hydroxyquinolinone ayant une activité d'antagoniste des récepteurs muscariniques et d'agoniste des récepteurs adrénergiques bêta2
CA2994290C (fr) 2017-11-06 2024-01-23 Entech Solution As Methode et manchon de stimulation destines a la completion de puits dans un puits de forage souterrain
EP4365162A3 (fr) * 2020-12-21 2024-10-09 Intervet International B.V. Procédé de préparation de n-(bis(4-méthoxyphényl)méthyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222128A (en) 1937-01-29 1940-11-19 Pure Oil Co Preparation and separation of aromatic hydrocarbons
DE19921693A1 (de) 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
MXPA05003866A (es) 2002-10-11 2005-06-22 Pfizer Derivados de indol como agonistas beta-2.
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
ES2329586T3 (es) 2003-11-21 2009-11-27 Theravance, Inc. Compuestos que tienen actividad agonista del receptor beta2 adrenergico y antagonista del receptor muscarino.
ME00557A (en) 2004-01-22 2011-12-20 Sulfonamide derivatives for the treatment of diseases
WO2005092861A1 (fr) 2004-03-11 2005-10-06 Pfizer Limited Derives de quinolinone compositions pharmaceutiques contenant ces derives et utilisation de celles-ci
US7538141B2 (en) 2004-03-23 2009-05-26 Alan Daniel Brown Compounds for the treatment of diseases
PL1730103T3 (pl) 2004-03-23 2010-10-29 Pfizer Pochodne formamidu użyteczne jako adrenoreceptor
ES2257152B1 (es) 2004-05-31 2007-07-01 Laboratorios Almirall S.A. Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
JP2008510015A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス， インコーポレーテッド β２アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
FR2898640B1 (fr) 2006-03-20 2008-04-25 Siemens Vdo Automotive Sas Procede de transmission d'information relatif au fonctionnement d'un moteur a combustion interne
EP2080523A1 (fr) * 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Compositions comprenant un agent anti-muscarinique et un bêta-agoniste longue action
ES2635358T3 (es) 2009-04-23 2017-10-03 Theravance Respiratory Company, Llc Compuestos de diamina que tienen actividad antagonista del receptor muscarínico y agonista del receptor beta2 adrenérgico
CA2760630A1 (fr) * 2009-04-30 2010-11-04 Teijin Pharma Limited Compose sel d'ammonium quaternaire
WO2011048409A1 (fr) 2009-10-20 2011-04-28 Astrazeneca Ab Dérivés d'amine cyclique ayant une activité agoniste de récepteur adrénergique bêta-2 et antagoniste de récepteur muscarinique
BR112013031493B1 (pt) * 2011-06-10 2022-04-19 Chiesi Farmaceutici S.P.A Composto, composição farmacêutica, uso de um composto, combinação de um composto, dispositivo e processo de preparação de um composto
KR20180085068A (ko) 2011-06-10 2018-07-25 키에시 파르마슈티시 엣스. 피. 에이. 무스카린 수용체 길항제 및 베타2 아드레날린 수용체 작용제 효능을 갖는 화합물
SG10201704032RA (en) * 2012-12-06 2017-06-29 Chiesi Farm Spa Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
CN104854105B (zh) * 2012-12-06 2017-05-17 奇斯药制品公司 具有毒蕈碱受体拮抗剂和β2肾上腺素能受体激动剂活性的化合物

Also Published As

Publication number Publication date
KR102156443B1 (ko) 2020-09-17
LT3345904T (lt) 2020-09-25
IL239182A0 (en) 2015-07-30
EA030552B1 (ru) 2018-08-31
PE20151216A1 (es) 2015-09-08
SA515360514B1 (ar) 2016-08-30
ES2816210T3 (es) 2021-03-31
TR201808698T4 (tr) 2018-07-23
EP3345904B1 (fr) 2020-07-29
RS57232B1 (sr) 2018-07-31
CN104822678B (zh) 2017-03-08
CA2893626A1 (fr) 2014-06-12
KR20200027049A (ko) 2020-03-11
CN104822678A (zh) 2015-08-05
GEP20186839B (en) 2018-04-10
AU2013354043C1 (en) 2017-08-31
JP6421989B2 (ja) 2018-11-14
US9371318B2 (en) 2016-06-21
EP3345904A1 (fr) 2018-07-11
ZA201503965B (en) 2016-09-28
CA2893626C (fr) 2021-08-24
IL239182B (en) 2018-12-31
SG10201704032RA (en) 2017-06-29
EP2928889A1 (fr) 2015-10-14
US8987299B2 (en) 2015-03-24
SI3345904T1 (sl) 2020-09-30
MX369311B (es) 2019-11-05
PH12015501247A1 (en) 2015-08-17
PL3345904T3 (pl) 2020-12-14
PL2928889T3 (pl) 2018-09-28
SI2928889T1 (en) 2018-05-31
UA118181C2 (uk) 2018-12-10
ES2670686T3 (es) 2018-05-31
RS60864B1 (sr) 2020-11-30
US20150133491A1 (en) 2015-05-14
DK2928889T3 (en) 2018-05-22
TWI637954B (zh) 2018-10-11
PT2928889T (pt) 2018-05-29
HUE037944T2 (hu) 2018-09-28
JP2016502557A (ja) 2016-01-28
AR093825A1 (es) 2015-06-24
AU2013354043B2 (en) 2017-06-15
HK1212989A1 (zh) 2016-06-24
MX2015006788A (es) 2015-08-05
CL2015001483A1 (es) 2015-10-23
TW201427976A (zh) 2014-07-16
PH12015501247B1 (en) 2019-02-06
MA38147A1 (fr) 2018-03-30
KR20150090108A (ko) 2015-08-05
BR112015012730B1 (pt) 2022-07-05
NZ708738A (en) 2019-02-22
US20140161736A1 (en) 2014-06-12
HUE051394T2 (hu) 2021-03-01
CY1120159T1 (el) 2018-12-12
WO2014086924A1 (fr) 2014-06-12
CO7400870A2 (es) 2015-09-30
CY1123365T1 (el) 2021-12-31
BR112015012730A2 (pt) 2017-07-11
EP2928889B1 (fr) 2018-03-21
PT3345904T (pt) 2020-09-07
HRP20180915T1 (hr) 2018-07-27
TN2015000244A1 (en) 2016-10-03
EA201590873A1 (ru) 2015-09-30
SG11201504318UA (en) 2015-07-30
LT2928889T (lt) 2018-06-11
DK3345904T3 (da) 2020-08-31
KR102240459B1 (ko) 2021-04-16
HRP20201435T1 (hr) 2020-11-27

Similar Documents

Publication Publication Date Title
MA38147A1 (fr) Composés ayant une activité antagoniste du récepteur muscarinique et agoniste du récepteur bêta2 adrénergique
MA35187B1 (fr) Composés ayant une activité antagoniste d'un récepteur muscarinique et agoniste d'un récepteur béta2 adrénergique
MA38325A2 (fr) Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
BR112015012746A2 (pt) compostos que possuem atividade de antagonista de receptores muscarínicos e agonista de receptores beta2-adrenérgicos
EP2614860A4 (fr) Composition pharmaceutique pour le traitement de l'oeil sec
PH12017501424A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
MX2011011156A (es) COMPUESTOS DIAMIDA QUE TIENE ACTIVIDAD COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS Y COMO AGONISTAS DE LOS RECEPTORES ANDRENERGICOS ß2.
MA38260A1 (fr) Nouveaux dérivés de cyclohexyl et quinuclidinyl carbamate ayant une activité d'agoniste adrénergique beta2 et une activité d'antagoniste muscarinique m3
MY172806A (en) New cyclohexylamine derivatives having ?2 adrenergic agonist and m3 muscarinic antagonist activities
MA35893B1 (fr) Dérivés d'amide hétérocyclique comme antagonistes du récepteur p2x7
MA43256B1 (fr) Procédé pour préparer une formulation de poudre sèche comprenant un anticholinergique, un corticostéroïde et un bêta-adrénergique
MA35268B1 (fr) 1-pipérazino-3-phénylindanes deutérés pour le traitement de la schizophrénie
MA32061B1 (fr) Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments
MA32062B1 (fr) Sels de triazolium comme inhibiteurs de par1, leur production et leur utilisation comme médicaments
EA201001842A1 (ru) Новые соединения, обладающие активностью антагонистов мускариновых рецепторов
BR112017023484A2 (pt) compostos tendo atividade de antagonista de receptor muscarínico e agonista de receptor beta2 adrenérgico
PE20130813A1 (es) Nueva asociacion entre la 4-{3-[cis-hexahidrociclopenta[c]pirrol-2(1h)-il]propoxi}benzamida y un antagonista de los receptores nmda y las composiciones farmaceuticas que la contienen
TN2013000429A1 (en) Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity
UA109581C2 (uk) Сполуки з активністю антагоністів мускаринових рецепторів і агоністів адренергічного рецептора бета2
MA39054B1 (fr) Dérivés pyridyle bicycliques à anneaux fusionnés utilisés en tant qu'inhibiteurs de fgfr4